Skip to content
Search

Latest Stories

MHRA warning: Thousands of counterfeit anti-choking devices sold across the UK

MHRA warning: Thousands of counterfeit anti-choking devices sold across the UK

People are warned that use of unbranded devices could exacerbate the situation by pushing obstructions further down into the airway passage 

The Medicines and Healthcare products Regulatory Agency (MHRA) has advised the public to exercise caution when buying anti-choking devices online, ensuring these products are purchased from reputable sellers.


As estimated by the regulator, more than 10,000 counterfeit or unbranded anti-choking devices have been purchased by the public within the last two years through listings on online marketplaces such as Amazon and eBay, as well as drop-shipping websites.

People are cautioned that the use of such products poses a substantial risk of failure in clearing blockages and could exacerbate the situation by pushing obstructions further down into the airway passage.

Dr Alison Cave, MHRA Chief Safety Officer, said: “Buying anti-choking devices that do not have a valid UKCA or CE mark increases the risk of receiving a product which does not include appropriate instructions and is either fake or does not meet the UK’s regulatory requirements.

“These products do not meet our strict quality standards and may put your health and safety at significant risk by failing to resolve or even worsening choking incidents.”

Currently, two anti-choking device brands, LifeVac and Dechoker, have a valid UKCA or CE mark and are authorised by the MHRA to be used after Basic Life Support protocols have been attempted and proved ineffective.

According to the regulator, most counterfeit or unbranded anti-choking devices are manufactured or shipped from China. These fake products resemble the design of the LifeVac device and, in some cases, claim to be the genuine brand.

“None of the anti-choking devices registered with the MHRA are manufactured in China. Any products shipped from China should be treated with caution and disposed,” the MHRA warning said.

How to check whether the device is genuine or counterfeit?

Photos highlighting the differences between a genuine and a counterfeit anti-choking device are provided in the Device Safety Information alert released by the MHRA

Key distinctions between a genuine and counterfeit device are highlighted here.

Screenshot 2024 03 25 225140

Screenshot 2024 03 25 225234

Screenshot 2024 03 25 225308

Screenshot 2024 03 25 225407

Buyers can also contact the legal manufacturer, LifeVac, which can verify the legitimacy of a purchased product against their records of authorised distributors and product serial numbers.

However, the MHRA has not received any reports regarding adverse incidents related to anti-choking devices.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less